Sorbonne Université, Inserm, Nutrition and Obesities: Systemic Approaches (Nutriomics), Paris, France.
Assistance Publique Hôpitaux de Paris, Visceral Surgery Department, Pitié-Salpêtrière Hospital, Paris, France.
Diabetologia. 2021 Jan;64(1):240-254. doi: 10.1007/s00125-020-05307-0. Epub 2020 Oct 30.
AIM/HYPOTHESIS: Altered adipose tissue secretory profile contributes to insulin resistance and type 2 diabetes in obesity. Preclinical studies have identified senescent cells as a cellular source of proinflammatory factors in adipose tissue of obese mice. In humans, potential links with obesity comorbidities are poorly defined. Here, we investigated adipose tissue senescent status and relationships with metabolic complications in human obesity.
The study includes a prospective cohort of 227 individuals with severe obesity. A photometric method was used to quantify senescence-associated β-galactosidase (SA-β-gal) activity in paired subcutaneous and omental adipose tissue biopsies obtained during gastric surgery. Gene and secretory profiling was performed in adipose tissue biopsies and in human primary pre-adipocytes in the presence or absence of senolytic drugs targeting senescent cells. Participants were phenotyped for anthropometric and bioclinical variables, metabolic complications and gastric surgery-induced improvement to address relationships with adipose tissue SA-β-gal.
SA-β-gal activity was sevenfold higher in subcutaneous than in omental adipose tissue and not associated with BMI or chronological age. Several factors, including insulin-like growth factor binding protein 3 (IGFBP3), plasminogen activator inhibitor 1 (PAI1), C-C motif chemokine ligand 2 (CCL2) and IL-6, were upregulated in subcutaneous adipose tissue in relation with SA-β-gal (p for linear trend across tertiles <0.05) and in pre-adipocytes cultured with inflammatory macrophage conditioned media. Senolytic treatment reduced SA-β-gal staining and normalised these alterations. In the whole population, subcutaneous adipose tissue SA-β-gal activity was positively associated with serum leptin, markers of insulin resistance and increased trunk fat mass. Metabolic complications, including type 2 diabetes and dyslipidaemia, were more prevalent in patients with high levels of SA-β-gal, but improved with bariatric surgery whatever the initial adipose tissue senescent status.
CONCLUSIONS/INTERPRETATION: This study highlights a phenotype of senescence in adipose tissue of severely obese individuals, which characterises prominently subcutaneous fat depots. Subcutaneous adipose tissue senescence is significantly linked to altered glucose metabolism and body fat distribution. Elimination of senescent cells through senolytic treatment could alleviate metabolic complications in severely obese people. Graphical abstract.
目的/假设:脂肪组织分泌谱的改变导致肥胖患者发生胰岛素抵抗和 2 型糖尿病。临床前研究已经确定衰老细胞是肥胖小鼠脂肪组织中促炎因子的细胞来源。在人类中,与肥胖合并症的潜在联系尚未明确界定。在这里,我们研究了人类肥胖症中脂肪组织衰老状态与代谢并发症的关系。
该研究纳入了 227 名严重肥胖患者的前瞻性队列研究。在胃外科手术中获得的配对皮下和网膜脂肪组织活检中,使用比色法来量化衰老相关的β-半乳糖苷酶(SA-β-gal)活性。在存在或不存在针对衰老细胞的衰老细胞清除药物的情况下,对脂肪组织活检和人原代前体脂肪细胞进行基因和分泌谱分析。对参与者进行人体测量学和生物临床变量、代谢并发症以及胃外科手术改善情况的表型分析,以探讨与脂肪组织 SA-β-gal 的关系。
与网膜脂肪组织相比,SA-β-gal 在皮下脂肪组织中的活性高 7 倍,与 BMI 或实际年龄无关。包括胰岛素样生长因子结合蛋白 3(IGFBP3)、纤溶酶原激活物抑制剂 1(PAI1)、C 型趋化因子配体 2(CCL2)和白细胞介素 6 在内的多种因子与 SA-β-gal 呈正相关(三分位组间 p 值<0.05),并与培养在炎症性巨噬细胞条件培养基中的前体脂肪细胞相关。衰老细胞清除治疗减少了 SA-β-gal 染色并使这些改变正常化。在整个人群中,皮下脂肪组织 SA-β-gal 活性与血清瘦素、胰岛素抵抗标志物和躯干脂肪量增加呈正相关。代谢并发症,包括 2 型糖尿病和血脂异常,在 SA-β-gal 水平较高的患者中更为常见,但无论初始脂肪组织衰老状态如何,减重手术都可以改善这些并发症。
结论/解释:这项研究强调了严重肥胖个体脂肪组织中衰老表型的存在,该表型主要表现为皮下脂肪组织。皮下脂肪组织衰老与葡萄糖代谢和体脂分布的改变显著相关。通过衰老细胞清除治疗可以减轻严重肥胖人群的代谢并发症。